BioLife Solutions (BLFS) Form 4 details director stock sales

Rhea-AI Filing Summary

BioLife Solutions Inc. (BLFS) reported an insider stock sale by a board director. Director Amy DuRoss filed a Form 4 disclosing three open-market sales of BLFS common stock on 11/19/2025, 11/20/2025, and 11/21/2025. The reported transactions were sales of 477 shares at $24.50, 4,523 shares at $24.51, and 1,000 shares at $26.00, all coded as dispositions. After these trades, DuRoss beneficially owned 24,687 shares of BioLife Solutions common stock in direct ownership.

Insider Trade Summary

Net Seller: 6,000 shares ($148,545)

Net Sell 3 txns

Insider DuRoss Amy

Role Director

Sold 6,000 shs ($149K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,000	$26.00	$26K
Sale	Common Stock	4,523	$24.51	$111K
Sale	Common Stock	477	$24.50	$12K

Holdings After Transaction: Common Stock — 24,687 shares (Direct)

Footnotes (1)

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

DuRoss Amy

(Last) (First) (Middle)

3303 MONTE VILLA PARKWAY

SUITE 310

(Street)

BOTHELL WA 98021

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIOLIFE SOLUTIONS INC [ BLFS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/19/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/19/2025		S		477	D	$24.5	30,210	D
Common Stock	11/20/2025		S		4,523	D	$24.51	25,687	D
Common Stock	11/21/2025		S		1,000	D	$26	24,687	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

	/s/ Amy DuRoss	11/21/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does the BLFS Form 4 filing report?

The Form 4 reports that Amy DuRoss, a director of BioLife Solutions Inc. (BLFS), sold shares of the company’s common stock in three transactions and updated her remaining holdings.

How many BLFS shares did director Amy DuRoss sell?

Amy DuRoss reported selling 477 BLFS common shares at $24.50 on 11/19/2025, 4,523 shares at $24.51 on 11/20/2025, and 1,000 shares at $26.00 on 11/21/2025.

How many BLFS shares does Amy DuRoss own after these transactions?

Following the reported sales, Amy DuRoss beneficially owned 24,687 shares of BioLife Solutions common stock, held in direct ownership.

What is Amy DuRoss’s relationship to BioLife Solutions (BLFS)?

Amy DuRoss is identified in the filing as a director of BioLife Solutions Inc. (BLFS).

Were any derivative securities reported in this BLFS Form 4?

The Form 4 includes a section for derivative securities, but no derivative security transactions were reported in the provided table.

Were the BLFS shares sold directly or indirectly by the reporting person?

The filing indicates that the BLFS common stock transactions and the 24,687 shares owned after the trades are held with direct ownership.